A Pivotal, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety of TAK-242 in Adults With Severe Sepsis.
Phase of Trial: Phase III
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Resatorvid (Primary)
- Indications Sepsis
- Focus Registrational; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 09 Nov 2012 Planned number of patients changed from 277 to 2930 as reported by European Clinical Trials Database record.
- 08 Nov 2007 Updated number of patients from 2930 to 277.